Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

M 003

Next Previous
Drug Profile

M 003

Alternative Names: M-003

Latest Information Update: 04 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MGFB Bio
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 04 Sep 2025 M 003 is still in preclinical development for Colorectal cancer (MGFB Bio pipeline, August 2025)
  • 03 Jan 2023 Preclinical trials in Colorectal cancer in USA (unspecified route) (MGFB Bio pipeline, January 2023; Greenfire Bio pipeline, January 2023)
  • 08 Nov 2022 MGFB Bio and Mayo clinic has entered into a patent license agreement for the development of therapeutic cancer vaccines

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top